Business Context and Reporting Period
This Form 8-K reports on events occurring on November 14, 2024, for Invizyne Technologies Inc. (trading symbol: IZTC). The filing details the consummation of the Company's Initial Public Offering (IPO) and related transactions. The Company is incorporated in Nevada and its common stock began trading on the Nasdaq Capital Market on November 13, 2024.
Key Financial Metrics and Capital Raised
- IPO Proceeds: The Company sold 1,875,000 shares of common stock at $8.00 per share.
- Net Proceeds: The Company received $14,321,686 in net proceeds from the IPO after deducting underwriting discounts, commissions, and estimated offering expenses.
- Concurrent Private Offering: The Company issued 93,750 private warrants at $0.125 per warrant, generating gross proceeds of approximately $11,719.
- SAFE Conversion: On November 14, 2024, 125,001 shares of common stock were issued upon the conversion of Simple Agreements for Future Equity (SAFEs) previously issued to MDB Capital Holdings LLC and Paul Opgenorth.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, or debt figures for the reporting period.
Material Changes and Agreements
The primary material change is the transition from a private entity to a public company via the IPO. Key contractual obligations include:
- Over-Allotment Option: The underwriter, MDB Capital, holds a 45-day option to purchase up to 281,250 additional shares to cover over-allotments.
- Underwriter's Warrants: The Company granted warrants to purchase up to 150,000 shares at an exercise price of $10.00 per share, exercisable for five years.
- Private Warrants: Private warrants have an exercise price of $8.00 per share, are exercisable beginning six months after issuance, and expire in five years. If fully exercised for cash, they could yield up to $750,000.
- Lock-Up Agreements: The Company, directors, and executive officers are subject to a one-year lock-up period prohibiting the sale or disposition of common stock or convertible securities.
Guidance, Outlook, and Risks
The filing states that the Company intends to use the net proceeds for purposes set forth in the IPO prospectus, though specific allocation details are not included in this text. The Company is designated as an emerging growth company.
Risks and Contingencies: The filing references customary representations, warranties, and indemnification obligations in the Underwriting Agreement. The private warrants include anti-dilution rights and blocker provisions. The text does not provide specific management commentary on future financial performance or detailed risk factors beyond the standard contractual terms.
Investor Verification Checklist
- Verify the final use of the $14.3 million in net proceeds as detailed in the full IPO prospectus (Registration Statement File No. 333-276987).
- Confirm the status of the 45-day over-allotment option held by MDB Capital.
- Review the full text of the Underwriting Agreement and Private Warrant agreements filed as exhibits for specific indemnification and anti-dilution terms.
- Monitor the one-year lock-up expiration date for insiders and the six-month vesting period for private warrant exercisability.